ClinicalTrials.gg
RecruitingNCT07347951Updated Jan 16, 2026

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

A Phase 2 interventional study of Short-course radiotherapy and CAPOX chemotherapy in Locally Advanced Rectal Cancer (LARC), sponsored by First Affiliated Hospital of Wenzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies testing capecitabine in Rectal Neoplasms — 18 open to participants now, 28 under way, 4 of them phase 3. Capecitabine · Rectal Neoplasms.

Planned enrollment
87th of 130
30 · median 49
Started
2025
with 2 others
Phase 2
85 of 136
13 open now
Primary completion
2027-12
later than 22 of 27 live
Registered
134th of 136
by date

Among the 136 studies testing capecitabine in Rectal Neoplasms, this one is the 87th largest by planned enrollment of the 130 interventional ones that give a count, is one of 3 that started in 2025, is one of 85 in phase 2, reaches primary completion later than 22 of the 27 other live ones, and was the 134th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

18 of the 136 studies testing capecitabine in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing capecitabine in Rectal Neoplasms, or all of them as a file.
02

Study summary

In a single-center, prospective, phase II study (ClinicalTrials registration number: [to be filled in]) initiated by our center to evaluate the safety and preliminary efficacy of short-course radiotherapy followed by sequential CAPOX chemotherapy combined with serplulimab and bevacizumab as total neoadjuvant therapy for MSS-type mid-low locally advanced rectal cancer, patients with mid-low MSS-type locally advanced rectal adenocarcinoma were enrolled. They received short-course radiotherapy combined with CAPEOX, serplulimab, and bevacizumab as preoperative total neoadjuvant therapy. It is anticipated that 30 subjects with locally advanced rectal cancer will be enrolled between September 2025 and September 2027.

This phase II exploratory study targets patients with locally advanced mid-low MSS/pMMR rectal cancer. It employs short-course radiotherapy combined with CAPEOX, serplulimab, and bevacizumab as preoperative total neoadjuvant therapy, aiming to clarify the efficacy and safety of this new combined radiotherapy, chemotherapy, targeted therapy, and immunotherapy approach, while also assessing the rectal/anal preservation rate and quality of life of patients. After neoadjuvant therapy, patients will undergo imaging and endoscopic evaluations to determine subsequent treatment strategies. Radical surgical resection will be performed on patients after neoadjuvant immunotherapy, followed by further analysis of the pathological complete response (pCR) rate. The primary study endpoint is the pCR rate, and secondary study endpoints include the objective response rate, organ preservation rate, 3-year disease-free survival (DFS), 3-year overall survival (OS), incidence of adverse events, and quality of life scores (EORTC QLQ-C30, EORTC QLQ-CR29, Wexner).

03

Conditions studied

  • Locally Advanced Rectal Cancer (LARC)

Browse trials for

Keywords

  • Rectal cancer
  • MSS
  • neoadjuvant immunotherapy
  • neoadjuvant chemoradiotherapy
  • Target therapy
  • locally advanced
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have a desire to preserve the anus and are willing to receive the entire course of therapy.

    • Aged between 18 and 75 years, with no gender restrictions.

      • Diagnosed via pelvic MRI and rectoscopy with a tumor located ≤10 cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes confined within the mesorectum.

        • diagnosed with rectal adenocarcinoma; genetic testing indicates MSS or MSI-L, or immunohistochemistry of tumor indicates pMMR (positive for MSH1, MSH2, MSH6, and PMS2 proteins).

          • performance status score of 0-1.

            ⑥ No prior antitumor therapy, immunotherapy, anti-angiogenic therapy, or pelvic radiotherapy before inclusion.

            ⑦ Laboratory tests must meet the following criteria: i. White blood cell count ≥3.5×10⁹/L, ≥1.8×10⁹/L, count ≥100×10⁹/L, and ≥100 g/L; ii. ≤1.5, and APTT ≤1.5 times the , or partial thromboplastin time (PTT) ≤1.5 times the upper limit of normal; iii. Total ≤1.25 times the upper limit of normal; and AST ≤3 times the upper limit of normal; serum albumin ≥28 g/L; iv. 24-hour rate ≥50 mL/min or serum creatinine ≤1.5 times the upper limit of normal.

            ⑧ Willing to participate in this study voluntarily, sign the form, and comply with the scheduled outpatient visits and related procedural requirements to complete follow-up.

Exclusion criteria

Exclusion Criteria:

  • In addition to a confirmed diagnosis of rectal cancer, there is a current or past history of active malignant tumors.

    • Patients with to other sites indicated by preoperative staging.

      • Patients with suspicious positive lymph nodes in non-draining areas of the rectum, such as the internal and external iliac lymph nodes, as assessed by preoperative MRI or CT.

        • Patients requiring emergency surgery due to complications such as intestinal obstruction, intestinal perforation, or intestinal hemorrhage.

          • Patients with severe comorbid conditions and an estimated of ≤5 years.

            • Patients with known allergies to any components in the study.

              ⑦ Patients who have received or systemic therapy for immunosuppressive purposes within 30 days prior to the initiation of study treatment.

              ⑧ Patients who have received any other drug treatment (including immunotherapy) or participated in another interventional clinical trial within 30 days prior to screening.

              ⑨ Patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases requiring combined treatment (including psychiatric disorders), and severe laboratory abnormalities.

              ⑩ Patients with congenital or acquired immunodeficiency (such as infection).

              ⑪ Vulnerable populations, including individuals with psychiatric disorders, cognitive impairments, critically ill patients, minors, pregnant women, illiterate individuals, etc.

              ⑫ Other circumstances where, in the investigator's judgment, the patient is deemed unsuitable to participate in the clinical trial.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant chemoradiotherapy combined with ICIs and targeted therapy for MSS-type LARC

    Radiation: Short-course radiotherapy · Drug: CAPOX chemotherapy · Drug: Targeted therapy with bevacizumab · Drug: Serplulimab immunotherapy

Interventions

  • RadiationShort-course radiotherapy

    Radiotherapy adopts a short-course regimen, with a dose of 5\*5 Gy, administered once daily at 5 Gy per session for a total of 5 consecutive days of irradiation. It is recommended to use three-dimensional 3D-CRT or IMRT techniques. The irradiation fields include: (1) high-risk recurrence areas of the primary tumor, such as the tumor/tumor bed, mesorectal region, and presacral region. For middle and low rectal cancers, the target area should also encompass the ischioanal fossa; (2) regional lymphatic drainage areas, including the lymphatic drainage area along the common iliac vessels within the true pelvis, mesorectal region, lymphatic drainage area along the internal iliac vessels, and obturator lymph node region.

  • DrugCAPOX chemotherapy

    Drug pages: CapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OxaliplatinStudies of OxaliplatinOxaliplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chemotherapy with the CAPOX regimen: Capecitabine tablets are available in strengths of 0.5 g/tablet and 0.15 g/tablet; Oxaliplatin for injection is available in a strength of 0.1 g. The chemotherapy protocol is as follows: After a 7-day rest following radiotherapy, on Day 1 (D1), oxaliplatin is administered intravenously at a dose of 130 mg/m² over 2 hours; from Day 1 to Day 14 of each 3-week cycle, capecitabine is taken orally at a dose of 1000 mg/m² twice daily, with each cycle lasting 3 weeks.

  • DrugTargeted therapy with bevacizumab

    Drug page: BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Targeted therapy: On Day 1 (D1) of chemotherapy initiation, bevacizumab will be administered via infusion at a dose of 7.5 mg/kg, with each treatment course lasting 3 weeks, for a total of 6 courses.

  • DrugSerplulimab immunotherapy

    Immunotherapy: On Day 1 (D1) of chemotherapy initiation, administer 300 mg of serplulimab, with each treatment cycle lasting 3 weeks, for a total of 6 cycles.

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    In tumor specimens obtained from modified neoadjuvant chemoradiotherapy combined with immunotherapy followed by TME surgical resection, no cancer cells or local lymph node metastasis of cancer cells (ypT0N0M0) are observed under a microscope.

    Time frame: After the completion of these cycles, surgical treatment will be scheduled as appropriate (within 1-2 weeks) based on the assessment results. Pathological evaluation of the postoperative specimens will be conducted according to the tumor TRG criteria.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 24 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 16, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2030
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347951
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Responsible party
Pan Yifei (Chief Physician, First Affiliated Hospital of Wenzhou Medical University) — Principal investigator
First posted
Jan 16, 2026
Start date
Dec 1, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Jan 16, 2026

Study contacts

Yifei Pan, Master's Degree in Medicine
Contact
13506641535@139.com
86 13506641535

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin

Start the discussion